5-α-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review

BJU International

Volumn 106, Issue 10, 2010, Pages 1444-1451

  Wilt, Timothy J ^a   MacDonald, Roderick ^a   Hagerty, Karen ^c   Schellhammer, Paul ^d   Tacklind, James ^a   Somerfield, Mark R ^c   Kramer, Barnett S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

5 reductase inhibitor; prevention; prostate cancer; systematic review

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

CANCER DIAGNOSIS; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG WITHDRAWAL; EJACULATION; ERECTILE DYSFUNCTION; FAMILY HISTORY; GYNECOMASTIA; HEART FAILURE; HUMAN; LIBIDO; MONOTHERAPY; NEEDLE BIOPSY; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTICARCINOGENIC AGENTS; AZASTEROIDS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78349255053     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09714.x     Document Type: Review

References (20)

1. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24
2. Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
3. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS,. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 2008; 2: CD007091
4. Anonymous. Review Manager [Computer Program], Version 4.1. For Windows. Oxford: The Cochrane Collaboration, 2001
5. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60
6. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195-02
7. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
8. Andriole GL, Roehrborn C, Schulman KM, Slawin KM, Somerville M, Rittmaster RS,. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004; 64: 537-43
9. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996; 155: 1251-9
10. Cote RJ, Skinner EC, Salem CE, et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 1998; 78: 413-8
11. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185-91
12. Stoner E, Round E, Ferguson D, Gormley GJ,. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. J Urol 1994; 151: 1296-300
13. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate 1993; 22: 291-9
14. Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31
15. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS,. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin (CombAT) trial. Eur Urol 2010 (in press)
16. Ilic D, OConnor D, Green S, Wilt T,. Screening for prostate cancer. Cochrane Database Syst Rev 2010 (in press)
17. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1375-83
18. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-33
19. DAmico AV, Barry MJ,. Prostate cancer prevention and finasteride. J Urol 2006; 176: 2010-3
20. DAmico AV, Roehrborn CG,. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8: 21-5